Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12030751
Abstract: Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The… read more here.
Keywords: immunotherapy glioblastoma; glioblastoma current; future perspectives; shortcomings future ... See more keywords